Radioimmunotherapy — Hot New Treatment for Lymphoma

Abstract

Follicular lymphoma, one of the two most common lymphoid neoplasms in North America and Europe,¹ is diagnosed in approximately 15,000 adults in North America each year.² More than 90 percent of patients with this B-cell lymphoma have disseminated disease at diagnosis, and although the disease usually evolves slowly, most patients die of the lymphoma or complications of its treatment. Current treatments are effective in controlling the disease temporarily, often for years. The median overall survival from the time of diagnosis is approximately eight years, but survival is strongly influenced by age, the extent of disease, and the biology of the . . .